English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduMedicare could save up to 74% of the money lost from discarded Alzheimer’s drug lecanemab by the simple introduction of a new vial size that would reduce the amount of unused medication that is thrown away.
Tag: lecanemab
Molecule restores cognition, memory in Alzheimer’s disease model mice
In a new study, a molecule identified and synthesized by UCLA Health researchers was shown to restore cognitive functions in mice with symptoms of Alzheimer’s disease by effectively jumpstarting the brain’s memory circuitry.
Dr. Claudia Padilla discusses Alzheimer’s and a new treatment.
Claudia Padilla, MD, at Baylor Scott & White Health, discusses Alzheimer’s and a new treatment. What You Need to Know: Alzheimer’s disease is a type of dementia. The most common sign is short-term memory loss. New medication targets the protein…
Can a Blood Test Detect Alzheimer’s Disease?
In July, the first direct-to-consumer blood test designed to assess a user’s risk for developing Alzheimer’s disease hit the market.
Small Percentage of People with Early Dementia Eligible for New Alzheimer’s Drugs
Only a small percentage of older adults who are in the early stages of Alzheimer’s disease meet the eligibility criteria to receive new monoclonal antibody treatments, drugs that target amyloid-ß plaques in the brain, an early sign of Alzheimer’s disease. The new research is published in the August 16, 2023, online issue of Neurology®, the medical journal of the American Academy of Neurology. Clinical trial results for these drugs are only available in people in the early symptomatic stages of the disease, mild cognitive impairment or mild dementia due to Alzheimer’s disease.
Lecanemab FDA Approval: U-Mich Alzheimer’s disease expert available and quote #lecanemab
On July 6, the U.S. Food and Drug Administration granted full approval to the new Alzheimer’s disease drug lecanemab (brand name Leqembi). The medication was granted accelerated approval in January. With the landmark decision, University of Michigan Health, Michigan Medicine,…
Cedars-Sinai Experts Discuss Pros, Cons of New Alzheimer’s Drug
Cedars-Sinai patient care teams are preparing to offer lecanemab, a new Alzheimer’s disease treatment expected to soon receive approval from the U.S. Food and Drug Administration (FDA), to patients in the coming months.
Ahead of Lecanemab FDA Decision: University of Michigan #Alzheimers expert available for interview
The U.S. Food and Drug Administration is considering full approval of the new Alzheimer’s disease drug Lecanemab (brand name Leqembi), with a decision expected by July 6. University of Michigan Health, Michigan Medicine, has an expert available to talk about…
Annual Medicare spending could increase by $2 to $5 billion if Medicare expands coverage for dementia drug lecanemab
The anti-dementia medication lecanemab and its ancillary costs could add $2 billion to $5 billion in annual Medicare spending if the Centers for Medicare and Medicaid Services (CMS) revise their coverage decision. Currently, the medication is covered only for patients who are enrolled in clinical trials.
What to Know About the Recently Approved Alzheimer’s Drug
The U.S. Food and Drug Administration (FDA) recently granted approval to Lecanemab, the first Alzheimer’s disease treatment to win approval since the largely failed rollout of Aduhelm two years ago.
U-M Health neurologists available to discuss Lecanemab, Alzheimer’s drug FDA approval #lecanemab #alzheimers
The U.S. Food and Drug Administration granted accelerated approval Friday for lecanemab, an Alzheimer’s disease drug for which studies showed the promising biological effect of removal of the brain’s amyloid buildup that occurs in the disease. University of Michigan Health,…
MEDIA ADVISORY: Cedars-Sinai Experts On Hand to Discuss New Alzheimer’s Drug Now Under Review
The U.S. Food and Drug Administration is poised to make a decision on another new Alzheimer’s disease treatment this week, and experts from the Jona Goldrich Center for Alzheimer’s and Memory Disorders at Cedars-Sinai are available to explain how the drug works and which patients could benefit from the medication.